 7. Completion of standard induction chemotherapy planned defined as: At least 4 cycles of platinum doublet chemotherapy for metastatic disease with or without bevacizumab, if the patient is known to be EGFR mutation positive, erlotinib, afatinib, or gefitinib for 3 months, or for patients with known EML4-ALK fusions, crizotinib. Note that it is not mandatory to check EGFR mutation or EML4-ALK status prior to entry, but patients that receive options 2 or 3 should have had these molecular tests performed. 